The Cooper Companies, Inc.
Dec 5, 2013

The Cooper Companies Announces Fourth Quarter and Full Year 2013 Results

PLEASANTON, Calif., Dec. 5, 2013 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal fourth quarter and full year ended October 31, 2013.

Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "I am pleased to report record financial results for fiscal 2013 including record revenues at both of our business units and record EPS for the Company. We are proud of our many accomplishments throughout the year including CooperVision's success with its Biofinity® family of products and launch of MyDay along with CooperSurgical's success with its fertility franchise. As we enter fiscal 2014, we remain encouraged by our business trends and believe we are well positioned to deliver strong operating results."

Fourth Quarter GAAP Operating Highlights

Fourth Quarter CooperVision (CVI) GAAP Operating Highlights

        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  4Q13 4Q13 y/y y/y
Toric  $ 98.2 30% 7% 8%
Multifocal  31.8 10% 20% 19%
Single-use sphere  71.1 22% -2% 8%
Non single-use sphere, other  126.0 38% -1% 1%
Total  $ 327.1 100% 3% 6%
        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  4Q13 4Q13 y/y y/y
Americas  $ 141.7 43% 2% 2%
EMEA  114.3 35% 12% 8%
Asia Pacific  71.1 22% -7% 11%
Total  $ 327.1 100% 3% 6%
        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  4Q13 4Q13 y/y y/y
Silicone hydrogel  $ 146.9 45% 18% 19%
Proclear®  $ 81.6 25% 2% 4%

Fourth Quarter CooperSurgical (CSI) GAAP Operating Highlights

  (In millions) % of CSI Revenue %chg
  4Q13 4Q13 y/y
Office and surgical procedures  $ 55.8 66% 2%
Fertility  29.0 34% 24%
Total  $ 84.8 100% 8%

Fiscal Year 2013 Operating Highlights


2014 Guidance

The Company initiated its full year 2014 guidance. Guidance is summarized as follows:

  FY14 Guidance
Revenues (In millions)  
Total $1,675 - $1,735
CVI $1,355 - $1,395
CSI $320 - $340
GAAP $6.70 - $7.00
Non-GAAP $6.70 - $7.00

Guidance assumes constant currency at the date of issuance.

Reconciliation of Non-GAAP EPS to GAAP EPS

To supplement our financial results presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results. The non-GAAP measures exclude the loss on divestiture of Aime, discussed above, insurance proceeds related to a business interruption claim and costs related to acquisitions. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements and guidance prepared in accordance with GAAP. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. These non-GAAP measures are among the factors management uses in planning and forecasting for future periods.

In the fiscal first quarter of 2013, our non-GAAP results exclude $0.6 million of costs related to the acquisition of Origio recorded in selling, general and administrative expense and $14.1 million in business interruption insurance proceeds. Our fiscal fourth quarter of 2013 non-GAAP results exclude the $21.1 million loss on divestiture of Aime.

We also report revenue growth using the non-GAAP financial measure of constant currency revenue. Management presents and refers to constant currency information so that revenue results may be evaluated excluding the effect of foreign currency rate fluctuations. To present this information, current period revenue for entities reporting in currencies other than United States dollars are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year.

  Three Months Ended October 31, Twelve Months Ended October 31,
  2013 GAAP  Adjustments  2013 Non-GAAP 2013 GAAP  Adjustments  2013 Non-GAAP
Operating income  $ 62,043  $ 21,062  $ 83,105  $ 305,945  $ 21,687  $ 327,632
Income before income taxes  $ 61,092  $ 21,062  $ 82,154  $ 312,271  $ 7,604  $ 319,875
Provision for income taxes  $ 3,779  $ 4,699  $ 8,478  $ 15,365  $ 8,221  $ 23,586
Net income attributable to Cooper stockholders  $ 57,396  $ 16,363  $ 73,759  $ 296,151  $ (617)  $ 295,534
Diluted EPS attributable to Cooper stockholders  $ 1.15  $ 0.33  $ 1.48  $ 5.96  $ (0.01)  $ 5.95
  Fiscal 2014 EPS Guidance  
  2014 GAAP  Adjustments  2014 Non-GAAP      
Diluted EPS $6.70 - $7.00  $ --  $6.70 - $7.00      

Conference Call and Webcast

The Company will host a conference call today at 5:00 PM ET to discuss its fiscal fourth quarter and full year 2013 financial results and current corporate developments. The dial in number in the United States is +1-866-202-3048 and outside the United States is +1-617-213-8843. The passcode is 59457110. There will be a replay available approximately two hours after the call ends until Thursday, December 12, 2013. The replay number in the United States is +1-888-286-8010 and outside the United States is +1-617-801-6888. The replay passcode is 55887527. This call will also be broadcast live at, and a transcript will be available following the conference call. 

About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 8,000 employees with products sold in over 100 countries. For more information, please visit

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including our 2013 Guidance and all statements regarding anticipated growth in our revenue, expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing uncertainty and instability of certain European Union countries that could adversely affect our global markets; foreign currency exchange rate and interest rate fluctuations including the risk of further declines in the value of the yen and the euro that would decrease our revenues and earnings; acquisition integration delays or costs or the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period; a major disruption in the operations of our manufacturing, research and development or distribution facilities due to technological problems, natural disasters or other causes; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; the impact of acquisitions or divestitures on revenues, earnings or margins; limitations on sales following new product introductions due to poor market acceptance; new competitors, product innovations or technologies; reduced sales, loss of customers, and costs and expenses related to recalls; new U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect the medical device industry and the healthcare industry generally; failure to receive, or delays in receiving, U.S. or foreign regulatory approvals for products; failure to obtain adequate coverage and reimbursement from third party payors for our products; compliance costs and potential liability in connection with U.S. and foreign healthcare regulations, including product recalls, and potential losses resulting from sales of counterfeit and other infringing products; legal costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection or other litigation; changes in tax laws or their interpretation and changes in effective tax rates; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill; the success of the Company's research and development activities and other start-up projects; dilution to earnings per share from acquisitions or issuing stock; changes in accounting principles or estimates; environmental risks and other events described in our Securities and Exchange Commission filings, including the "Business" and "Risk Factors" sections in the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2012, as such Risk Factors may be updated in quarterly filings.

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Consolidated Condensed Balance Sheets
(In thousands)
  October 31, October 31,
  2013 2012
Current assets:    
Cash and cash equivalents  $ 77,393  $ 12,840
Trade receivables, net  229,537  234,297
Inventories  338,917  320,199
Deferred tax assets  41,179  39,417
Other current assets  60,215  51,107
Total current assets  747,241  657,860
Property, plant and equipment, net  739,867  640,255
Goodwill  1,387,611  1,370,247
Other intangibles, net  198,769  214,783
Deferred tax assets  16,279  14,434
Other assets  47,494  43,805
   $ 3,137,261  $ 2,941,384
Current liabilities:    
Short-term debt  $ 42,987  $ 25,284
Other current liabilities  278,266  237,268
Total current liabilities  321,253  262,552
Long-term debt  301,670  348,422
Deferred tax liabilities  24,883  30,971
Other liabilities  65,961  86,281
Total liabilities  713,767  728,226
Total Cooper stockholders' equity  2,404,535  2,192,751
Noncontrolling interests  18,959  20,407
Stockholders' equity  2,423,494  2,213,158
   $ 3,137,261  $ 2,941,384
Consolidated Statements of Income
(In thousands, except earnings per share amounts)
  Three Months Ended Year Ended
  October 31, October 31,
  2013 2012 2013 2012
Net sales   $ 411,852  $ 396,301  $ 1,587,725  $ 1,445,136
Cost of sales  147,994  143,537  560,917  521,126
Gross profit  263,858  252,764  1,026,808  924,010
Selling, general and administrative expense  157,247  152,363  610,735  564,903
Research and development expense  15,819  14,118  58,827  51,730
Amortization of intangibles  7,687  7,303  30,239  23,979
Loss on divestiture of Aime  21,062  --   21,062  -- 
Operating income  62,043  78,980  305,945  283,398
Interest expense  1,900  2,723  9,168  11,771
Gain on insurance proceeds  --   5,000  14,084  5,000
Loss on extinguishment of debt  --   --   --   1,404
Other income, net  949  1,382  1,410  229
Income before income taxes  61,092  82,639  312,271  275,452
Provision for income taxes  3,779  10,492  15,365  26,808
Net income  57,313  72,147  296,906  248,644
Loss (income) attributable to noncontrolling interests  83  (227)  (755)  (305)
Net income attributable to Cooper stockholders  $ 57,396  $ 71,920  $ 296,151  $ 248,339
Diluted earnings per share attributable to Cooper stockholders  $ 1.15  $ 1.46  $ 5.96  $ 5.05
Number of shares used to compute earnings per share attributable to Cooper stockholders  49,723  49,386  49,685  49,152

Soft Contact Lens Revenue Update

Worldwide Manufacturers' Soft Contact Lens Revenue
(U.S. dollars in millions; constant currency; unaudited)
  Calendar 3Q13 Trailing Twelve Months 2013
    Market CVI   Market CVI
  Market Change Change Market Change Change
Sales by Modality            
Single-use  $ 810 10% 18%  $ 3,000 10% 18%
Other  1,120 3% 8%  4,360 1% 8%
WW Soft Contact Lenses  $ 1,930 6% 10%  $ 7,360 5% 10%
Sales by Geography            
Americas   $ 765 7% 11%  $ 2,905 5% 10%
EMEA  540 4% 9%  2,075 3% 8%
Asia Pacific   625 6% 10%  2,380 5% 14%
WW Soft Contact Lenses  $ 1,930 6% 10%  $ 7,360 5% 10%
Source: Management estimates and independent market research


CONTACT: Kim Duncan

         Senior Director, Investor Relations


The Cooper Companies, Inc. Logo

Source: The Cooper Companies, Inc.

News Provided by Acquire Media